Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Publication type: Journal Article
Publication date: 2018-10-01
scimago Q1
wos Q1
SJR: 19.072
CiteScore: 70.4
Impact factor: 65.4
ISSN: 09237534, 15698041
PubMed ID:
29917046
Oncology
Hematology
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
|
|
|
Frontiers in Oncology
21 publications, 5.5%
|
|
|
Journal for ImmunoTherapy of Cancer
16 publications, 4.19%
|
|
|
Cancers
14 publications, 3.66%
|
|
|
Frontiers in Pharmacology
10 publications, 2.62%
|
|
|
Frontiers in Immunology
8 publications, 2.09%
|
|
|
European Journal of Cancer
7 publications, 1.83%
|
|
|
Immunotherapy
4 publications, 1.05%
|
|
|
Diagnostics
4 publications, 1.05%
|
|
|
ESMO Open
4 publications, 1.05%
|
|
|
International Journal of Molecular Sciences
3 publications, 0.79%
|
|
|
Current Oncology
3 publications, 0.79%
|
|
|
Cancer Immunology, Immunotherapy
3 publications, 0.79%
|
|
|
BMC Cancer
3 publications, 0.79%
|
|
|
Revue de Medecine Interne
3 publications, 0.79%
|
|
|
Journal of Thoracic Oncology
3 publications, 0.79%
|
|
|
Zeitschrift fur Gastroenterologie
3 publications, 0.79%
|
|
|
Advances in Experimental Medicine and Biology
3 publications, 0.79%
|
|
|
Endocrinology, Diabetes and Metabolism Case Reports
2 publications, 0.52%
|
|
|
Oncology Letters
2 publications, 0.52%
|
|
|
Praxis
2 publications, 0.52%
|
|
|
Journal of Immunotherapy
2 publications, 0.52%
|
|
|
World Journal of Clinical Cases
2 publications, 0.52%
|
|
|
Therapeutic Advances in Medical Oncology
2 publications, 0.52%
|
|
|
Abdominal Radiology
2 publications, 0.52%
|
|
|
Investigational New Drugs
2 publications, 0.52%
|
|
|
Supportive Care in Cancer
2 publications, 0.52%
|
|
|
Nature Cancer
2 publications, 0.52%
|
|
|
Journal of Hematology and Oncology
2 publications, 0.52%
|
|
|
Der Gynakologe
2 publications, 0.52%
|
|
|
5
10
15
20
25
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
Elsevier
78 publications, 20.42%
|
|
|
Springer Nature
72 publications, 18.85%
|
|
|
Frontiers Media S.A.
40 publications, 10.47%
|
|
|
MDPI
30 publications, 7.85%
|
|
|
Wiley
24 publications, 6.28%
|
|
|
Taylor & Francis
20 publications, 5.24%
|
|
|
BMJ
18 publications, 4.71%
|
|
|
SAGE
10 publications, 2.62%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
9 publications, 2.36%
|
|
|
Oxford University Press
9 publications, 2.36%
|
|
|
Georg Thieme Verlag KG
7 publications, 1.83%
|
|
|
AME Publishing Company
7 publications, 1.83%
|
|
|
Baishideng Publishing Group
5 publications, 1.31%
|
|
|
S. Karger AG
3 publications, 0.79%
|
|
|
Bioscientifica
2 publications, 0.52%
|
|
|
Spandidos Publications
2 publications, 0.52%
|
|
|
Hogrefe Publishing Group
2 publications, 0.52%
|
|
|
Society for Translational Oncology
2 publications, 0.52%
|
|
|
American Society of Clinical Oncology (ASCO)
2 publications, 0.52%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 0.52%
|
|
|
Cambridge University Press
2 publications, 0.52%
|
|
|
Editions E D K
1 publication, 0.26%
|
|
|
Impact Journals
1 publication, 0.26%
|
|
|
SLACK
1 publication, 0.26%
|
|
|
American Medical Association (AMA)
1 publication, 0.26%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.26%
|
|
|
Deutscher Arzte-Verlag GmbH
1 publication, 0.26%
|
|
|
The Korean Association of Immunobiologists
1 publication, 0.26%
|
|
|
Korean Society of Applied Pharmacology
1 publication, 0.26%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
382
Total citations:
382
Citations from 2024:
53
(13.88%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Haanen J. et al. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. 2018. Vol. 29. No. Suppl 4. p. iv264-iv266.
GOST all authors (up to 50)
Copy
Haanen J., Carbonnel F., Robert C., Kerr K. M., Peters S., Larkin J. E., Jordan K. G. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. 2018. Vol. 29. No. Suppl 4. p. iv264-iv266.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1093/annonc/mdy162
UR - https://doi.org/10.1093/annonc/mdy162
TI - Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T2 - Annals of Oncology
AU - Haanen, John
AU - Carbonnel, Franck
AU - Robert, C.
AU - Kerr, K M.
AU - Peters, S
AU - Larkin, James E.
AU - Jordan, Kenneth G.
PY - 2018
DA - 2018/10/01
PB - Elsevier
SP - iv264-iv266
IS - Suppl 4
VL - 29
PMID - 29917046
SN - 0923-7534
SN - 1569-8041
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2018_Haanen,
author = {John Haanen and Franck Carbonnel and C. Robert and K M. Kerr and S Peters and James E. Larkin and Kenneth G. Jordan},
title = {Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up},
journal = {Annals of Oncology},
year = {2018},
volume = {29},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1093/annonc/mdy162},
number = {Suppl 4},
pages = {iv264--iv266},
doi = {10.1093/annonc/mdy162}
}
Cite this
MLA
Copy
Haanen, John, et al. “Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.” Annals of Oncology, vol. 29, no. Suppl 4, Oct. 2018, pp. iv264-iv266. https://doi.org/10.1093/annonc/mdy162.